SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arrambide Georgina, Llaneza-González Miguel Ángel, Costa-Frossard França Lucienne, Meca-Lallana Virginia, Díaz Eva Fernández-, Moreno-Torres Irene, García-Domínguez Jose Manuel, Ortega-Suero Gloria, Ayuso-Peralta Lucía, Gómez-Moreno Mayra, Sotoca-Fernández Javier J, Caminero-Rodríguez Ana Belén, Rodríguez de Antonio Luis A, Corujo-Suárez Marcial, Otano-Martínez María A, Pérez-Miralles Francisco Carlos, Reyes-Garrido Virginia, Ayuso-Blanco Teresa, Balseiro-Gómez José Jesús, Muñoz-Pasadas Mercedes, Pérez-Molina Inmaculada, Arnal-García Carmen, Domingo-Santos Ángela, Guijarro-Castro Cristina, Íñiguez-Martínez Cristina, Téllez Lara Nieves, Castellanos-Pinedo Fernando, Castillo-Triviño Tamara, Cerdán-Santacruz Debora María, Pérez-Sempere Ángel, Torres Berta Sebastián, Álvarez de Arcaya Amaya, Costa-Arpín Eva, Durán-Ferreras Eduardo, Fragoso-Martínez Marta, González-Platas Montserrat, Landete Pascual Lamberto, Millán-Pascual Jorge, Oreja-Guevara Celia, Meca-Lallana José E
Аннотация
METHODS: Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome.
RESULTS: Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome.
CONCLUSIONS: This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.